Kamada Ltd.
KMDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 18, 2026
Scan Results
Daily timeframeKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Valued at $406.7M, KMDA is a small-cap name in its sector. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
Market Cap
$406.7M
Beta
0.15
P/E (TTM)
20.14
P/E (Fwd)
11.49
EPS (TTM)
$0.35
EPS (Fwd)
$0.61
ROE
8.0%
ROA
4.2%
Cash
$73.1M
Total Debt
$11.6M
Free CF
$11.1M
52W Change
-5.4%
Annual Financials
Cash vs Debt
With $73.1M in cash and $11.6M in debt, KMDA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $11.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 8.0%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.2% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $129.3M (2022) to $180.5M (2025), reflecting a 40% increase over the period.
With a beta below 0.7, Kamada Ltd. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, KMDA has financial flexibility that may help navigate uncertain periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Kamada Ltd.'s trajectory.